No profile data available.
Sellas Life Sciences Group, Inc. (SLS) is a healthcare company in the blood cancer treatment drugs industry, based in New York, United States, with about 15 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$26.86 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $256.55 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
Sellas Life Sciences reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$256.55 million as of December 4, 2025.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Kura Oncology, Inc. (KURA), Corvus Pharmaceuticals, Inc. (CRVS), OmniAb, Inc. (OABI), ADC Therapeutics SA (ADCT).